Evidence map›Paper›PMID 37405957›Full record

ArticleCancer biology & therapy2023

VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcoma.

Shuo Yang, Ping Zhou, Lelei Zhang, Xiangpeng Xie, Yuanyi Zhang, Kaida Bo, Jing Xue, Wei Zhang, Faxue Liao, Pengfei Xu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancer biology & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Shuo YangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ping ZhouDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Lelei ZhangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiangpeng XieDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yuanyi ZhangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Kaida BoDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jing XueDepartment of Orthopaedics, Anhui Public Health Clinical Center, Hefei, China.
Wei ZhangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Faxue LiaoDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Pengfei XuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yong HuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ruyu YanCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.
Dan LiuCancer Metabolism Laboratory, School of Life Sciences, Anhui Medical University, Hefei, China.
Jun ChangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0002-6000-0358
Kecheng ZhouDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0003-1753-2524
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a highly metastatic malignant bone tumor, necessitating the development of new treatments to target its metastasis. Recent studies have revealed the significance of VAMP8 in regulating various signaling pathways in various types of cancer. However, the specific functional role of VAMP8 in osteosarcoma progression remains unclear. In this study, we observed a significant downregulation of VAMP8 in osteosarcoma cells and tissues. Low levels of VAMP8 in osteosarcoma tissues were associated with patients' poor prognosis. VAMP8 inhibited the migration and invasion capability of osteosarcoma cells. Mechanically, we identified DDX5 as a novel interacting partner of VAMP8, and the conjunction of VAMP8 and DDX5 promoted the degradation of DDX5 via the ubiquitin-proteasome system. Moreover, reduced levels of DDX5 led to the downregulation of β-catenin, thereby suppressing the epithelial-mesenchymal transition (EMT). Additionally, VAMP8 promoted autophagy flux, which may contribute to the suppression of osteosarcoma metastasis. In conclusion, our study anticipated that VAMP8 inhibits osteosarcoma metastasis by promoting the proteasomal degradation of DDX5, consequently inhibiting WNT/β-catenin signaling and EMT. Dysregulation of autophagy by VAMP8 is also implicated as a potential mechanism. These findings provide new insights into the biological nature driving osteosarcoma metastasis and highlight the modulation of VAMP8 as a potential therapeutic strategy for targeting osteosarcoma metastasis.

Indexed as

Bone NeoplasmsOsteosarcomabeta CateninCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansR-SNARE ProteinsWnt Signaling Pathwaybeta CateninR-SNARE ProteinsVAMP8 protein, humanDDX5metastasisOsteosarcomaVAMP8β-catenin

Identifiers

PMID37405957
PMCPMC10324439
OpenAlexW4383216958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.